OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - NOVO-NORDISK B | Market Closed - Deutsche Boerse AG 01:12:25 08/06/2024 am IST | ||
| 2.31 EUR | -9.41% |
|
| Current month | -27.13% | ||
| 1 month | -37.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 07/24/07 | 2.31 | -9.41% |
| 06/24/06 | 2.55 | 0.00% |
| 05/24/05 | 2.55 | -5.56% |
| 04/24/04 | 2.7 | -13.18% |
| 03/24/03 | 3.11 | -1.89% |
Delayed Quote Deutsche Boerse AG
Last update June 08, 2024 at 01:12 am IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SU01F8 |
| ISIN | DE000SU01F81 |
| Date issued | 23/10/2023 |
| Strike | 1,162 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.51 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.95 € |
|---|---|
| Lowest since issue | 2.28 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
984
DKK
Average target price
920.8
DKK
Spread / Average Target
-6.43%
- Stock Market
- Certificates
- Certificat
